Sentinel node biopsy for melanoma

Call for a balanced view on sentinel node biopsy for melanoma

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f648 (Published 6 February 2013)
Cite this as: BMJ 2013;346:f648

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jenny L C Geh, consultant plastic surgeon1,
  2. Ciaran Healy, consultant plastic surgeon1,
  3. Katie Lacy, consultant dermatologist1,
  4. Mary Wain, consultant dermatologist1,
  5. Natalie Attard, consultant dermatologist1,
  6. Eduardo Calonje, consultant dermatopathologist,
  7. Mark Harries, consultant oncologist1,
  8. Michael O’Doherty, consultant in nuclear medicine1,
  9. Danuta Orlowska, clinical psychologist for skin cancer service1
  1. 1Guy’s and St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London SE1 7EH, UK
  1. jenny.geh{at}gstt.nhs.uk

The title of Torjesen’s article could be misleading.1 Sentinel node biopsy (SNB) is a staging tool used to provide patients with the best available information,2 and is a well established prognostic test.

Our research shows that patients want information on prognosis.3 Lymph node status is the most meaningful prognostic indicator and SNB the most sensitive …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL